TrialInternational journal of hematology2015

A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.

Kenji Oritani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.